Sakar Healthcare's Oncology-Led Transformation Drives Stellar Q3 FY26 Performance

Sakar Healthcare Limited, an API-integrated pharmaceutical organization, has reported a remarkable performance for the third quarter and nine months ended December 31, 2025. The company's strategic pivot towards oncology, coupled with robust operational execution, has resulted in significant financial growth, positioning it as a formidable player in the global healthcare landscape. For Q3 FY26, Sakar Healthcare posted a consolidated revenue from operations of INR 70.34 crores, marking a substantial 62% year-on-year (YoY) increase. This impressive top-line growth translated into a 58% YoY rise in EBITDA to INR 18.59 crores, with EBITDA margins standing at a healthy 26%. The profit after tax (PAT) saw an even more dramatic surge, climbing 126% YoY to INR 10.25 crores, reflecting strong operating leverage and an improved product mix.

The nine-month period (9MFY26) also showcased robust performance, with revenue from operations reaching INR 180.64 crores, a 42% increase over the previous year. EBITDA for 9MFY26 grew by 26% to INR 42.65 crores, and PAT increased by 66% to INR 19.46 crores. These figures underscore the scalability of Sakar's integrated oncology operations and the growing global acceptance of its high-compliance manufacturing standards.

Oncology: The Driving Force

The oncology segment has emerged as the primary growth engine for Sakar Healthcare. In Q3 FY26, the oncology business alone contributed INR 31 crores to the total turnover, with INR 19 crores from exports, predominantly to the EU, and INR 12 crores from domestic sales. For the nine-month period, oncology revenues stood at INR 69.45 crores, comprising INR 30.81 crores from exports and INR 8.62 crores from domestic sales. This significant contribution highlights the success of the company's strategic focus on high-potency cancer therapies.

Sakar's state-of-the-art, EU-GMP approved oncology facility at Bavla, Gujarat, is a key differentiator. This vertically integrated plant boasts API and FDF capabilities, enabling the production of oral solids, oral liquids, sterile injections (liquid & lyophilised), and oncology APIs. The facility's approval as a manufacturing source for product supplies to the EU marks a major milestone, validating its capability to serve stringent regulated markets.

Financial Summary Table (INR Crores)

Strategic Initiatives and Market Penetration

Sakar Healthcare's diversified business model, encompassing CDMO Services, Own Brand Exports, and Product Development Technology Transfer, provides a balanced approach to stability and strategic growth. The company markets its own branded formulations across more than 60 countries, including APAC, Latin America, Africa, CIS, and Europe, with own brand exports now accounting for over 70% of its revenue, significantly enhancing profitability.

Research and development efforts are robust, with 55 oncology molecules developed and 32 dossiers ready for launch. The company has secured 11 Marketing Authorisations (MAs) in the EU and globally. Furthermore, 102 out of 211 oncology dossiers have been submitted across partner markets, with 11 already receiving approval. Sakar is also actively developing advanced formulations such as Liposomal (Doxorubicin) and HME-based products (Apalutamide, Olaparib, Enzalutamide), focusing on non-infringing patent formulations for regulated markets.

Product Development Snapshot

Sustainability and Outlook

Sakar Healthcare is deeply committed to sustainable and green manufacturing practices. The company employs advanced technologies like Flow Chemistry and GEA granulation lines, alongside Green Chemistry principles, Zero Liquid Discharge (ZLD) systems, and solar power. These initiatives not only ensure global compliance but also drive energy efficiency and waste reduction.

Looking ahead, management expects the strong momentum from Q3 to continue. They project a 60-70% year-on-year growth in the oncology business and over 40% overall revenue growth for FY26. The target EBITDA margin is around 30%, reflecting confidence in their strategic direction and operational efficiencies. With 100-plus marketing authorization submissions expected within the next 12 months and ongoing tech transfers for key molecules like Imatinib, Sakar Healthcare is well-positioned for sustained long-term value creation through global approvals and expanding partnerships.

The company's disciplined cost management, integrated oncology capabilities, and strong regulatory foundation are translating into a compelling growth story, making it a noteworthy entity in the Indian pharmaceutical sector.